Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Quality Data Made Accessible To Clinical Teams
NHS clinical teams will have access to data showing their performance against a set of more than 200 indicators of high quality care in the NHS in one place. It is the next phase in the drive to help NHS professionals improve the quality of care they deliver to patients, and will also support providers and commissioners of NHS services.
generic viagra online
Electronic Pill Shows Its Smarts By Measuring PH Levels In Digestive Tract
An electronic diagnostic tool called the SmartPill is swallowed by patients in order to take measurements as it travels through the gastrointestinal tract. A new study by physician-scientists at NewYork-Presbyterian/Weill Cornell Medical Center used the device in patients with mild to moderate ulcerative colitis (UC), determining that they have significantly more acidic pH in their colons, compared with the average person -- a finding that may impact treatment strategy.
News of the day
Following The Dietary Guidelines May Slow Heart Disease In Women
The Dietary Guidelines for Americans (DGA) provide guidance to promote health and reduce risk of chronic diseases. However, what evidence is there that following the DGA optimizes health? Is this advice useful for individuals already in poor health? To study these questions, researchers at the USDA Human Nutrition Research Center on Aging at Tufts University and Wake Forest University devised a statistical model that assessed adherence to the DGA and then related it to progression of atherosclerosis in women. Their results can be found in the July 2009 issue of the American Journal of Clinical Nutrition.
Oncology

Argenta Discovery And Porsolt Join Forces To Provide Fully-integrated CNS And Pain Contract Drug Discovery Services

Argenta Discovery and Porsolt announced they have entered into an alliance to provide unparalleled CNS and pain drug discovery services and expertise on a fee-for- service basis. The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for their clients, from hit identification to development candidate nomination. Both companies bring a wealth of "Big Pharma" industry based experience and know-how in CNS and pain research. This alliance will leverage those key skills for its partners to ensure the rapid generation of high quality development candidates. Dr. Christopher Ashton, CEO of Argenta said, "Argenta has undertaken many successful medicinal chemistry-driven CNS and pain contract drug discovery research projects, but we have been looking at ways of enhancing our capabilities in these important therapeutic areas. Argenta has partnered with Porsolt to provide clients with dedicated access to specialist CNS and pain models and expertise, offered by a world leader in the field. We have several ongoing contract research programmes in these therapeutic areas and a number of projects in the pipeline which are likely to benefit from Porsolt"s support and know-how. This alliance will enable Argenta to offer an even better integrated drug discovery service in the future. We are looking forward to working with Porsolt." Dr Mark Duxon, CEO of Porsolt added, "Porsolt is delighted to be entering into a partnership with Argenta to deliver full lead optimisation drug discovery on a contract research basis. Porsolt have recently announced a significant laboratory expansion in France and the Argenta partnership fits with our strategy of offering a diverse array of deal structure opportunities to suit the broad range of our clients" needs. Indeed, our increased business flexibility is entirely complementary to our client-oriented scientific expertise. Porsolt has always sought to deliver quality scientific solutions tailored to client needs. In this respect, we believe we have found a like minded partner in Argenta". Where there is a client need for outsourcing fully integrated drug discovery programmes for CNS and pain targets, Argenta and Porsolt offer a seamless drug discovery platform to the pharmaceutical industry, from hit identification to drug candidate selection. Should a client not be interested in a solution of this nature, both Porsolt and Argenta will continue to operate independently, offering their stand-alone contract research services spanning all therapeutic areas and drug target classes. Porsolt & Partners Pharmacology Argenta Discovery Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009